<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1764">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04732637</url>
  </required_header>
  <id_info>
    <org_study_id>U1111-1264-2742</org_study_id>
    <nct_id>NCT04732637</nct_id>
  </id_info>
  <brief_title>Concordance Between Buccal Cavity Swab and Nasopharyngeal Swab for Detection of SARS-CoV-2 Via RT-PCR and ELISA</brief_title>
  <official_title>Evaluating the Use of Flavoured Simulated Oral Fluids Collection Method for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and Enzyme Linked Immunosorbent Assay (ELISA) Method : A Concordance Study Plan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Datar Cancer Genetics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Test At Home</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National University, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Datar Cancer Genetics Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nasopharyngeal Swabs (NPS) used to test for Severe Acute Respiratory Syndrome Coronavirus 2&#xD;
      (SARS-CoV-2) infection can cause mild to severe discomfort in addition to increasing the risk&#xD;
      of transmission. The present study We evaluates Test At Home's proprietary self-collection&#xD;
      method based on a chewable buccal cavity swab (&quot;lollipop&quot;) that simulates oral fluid&#xD;
      collection. The novel method is compared against a contemporary nasal swab collected by a&#xD;
      qualified healthcare worker.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nasopharyngeal Swabs (NPS) are used to test for Severe Acute Respiratory Syndrome Coronavirus&#xD;
      2 (SARS-CoV-2) infection. For this, a swab is inserted deep into the back of the nose to&#xD;
      collect a sample. It can cause discomfort for most people. It also increases the risk of&#xD;
      transmission and other challenges. Researchers want to find an easier way to collect samples.&#xD;
      We are hypothesizing that our proprietary flavoured, stimulated saliva collection 'Lollipop'&#xD;
      swabbing (LPS) technology would concord with the NP samples.&#xD;
&#xD;
      The study aims to establish the outcome concordance of SARS-Cov-2 infection assessment via&#xD;
      Test At Home's proprietary &quot;lollipop&quot; buccal cavity swab that simulates oral fluid collection&#xD;
      via flavouring and mastication (self-collection) versus contemporary nasal swab collection&#xD;
      (health worker - collected).&#xD;
&#xD;
      For the present study, 300 pairs of matched nasopharyngeal swab (NPS) (health care worker&#xD;
      collected) and simulated oral fluid specimens (self-collected) will be obtained from 150&#xD;
      Coronavirus Disease -19 (COVID-19) positive patients and 150 COVID 19 negative individuals.&#xD;
&#xD;
      Test Method 1: Self-collected Test At Home's proprietary &quot;lollipop&quot; buccal cavity swab with&#xD;
      Viral Transport Medium (VTM) will be evaluated using the Standard 'TaqPath™' COVID-19&#xD;
      Conformité Européenne - In Vitro Diagnostic (CE-IVD) Reverse Transcriptase-Polymerase Chain&#xD;
      Reaction (RT-PCR) which is approved by the Indian Council of Medical Research (ICMR)&#xD;
&#xD;
      Test Method 2: Self-collected Test At Home's proprietary &quot;lollipop&quot; buccal cavity swab with&#xD;
      VTM will be evaluated using National University of Singapore (NUS) developed Enzyme Linked&#xD;
      Immunosorbent Assay (ELISA) Method.&#xD;
&#xD;
      Active Comparator : Health worker collected Nasopharyngeal Swab (NPS) with VTM which will be&#xD;
      evaluated using the Standard TaqPath™ COVID-19 CE-IVD RT-PCR which is approved by the Indian&#xD;
      Council of Medical Research (ICMR).&#xD;
&#xD;
      The diagnostic performance of using NPS and Oral fluids will be statistically compared to&#xD;
      determine three-way concordance and establish the performance characteristics of the Test&#xD;
      Methods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance between buccal cavity swab and contemporary nasal swab.</measure>
    <time_frame>Once, at first collection</time_frame>
    <description>Three-way concordance of SARS-Cov-2 infection assessment between Test At Home's &quot;Lollipop&quot; buccal cavity swab (assessed by RTPCR and ELISA) and contemporary nasal swab (assessed by RTPCR).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>COVID Positive</arm_group_label>
    <description>Individuals who have recently tested positive for COVID19 by RTPCR, with active infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID Negative</arm_group_label>
    <description>Individuals who have recently tested negative for COVID19 by RTPCR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Test At Home's Proprietary &quot;Lollipop&quot; Buccal Cavity Swab</intervention_name>
    <description>Self-collected Test At Home's proprietary &quot;Lollipop&quot; Buccal Cavity Swab with VTM.</description>
    <arm_group_label>COVID Negative</arm_group_label>
    <arm_group_label>COVID Positive</arm_group_label>
    <other_name>Self Collection Buccal Cavity Swab</other_name>
    <other_name>Buccal Cavity Swab</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biological samples collected via nasopharyngeal swaps and 'lollipop' buccal mucosa swabs and&#xD;
      used for extraction of viral nucleic acids&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult males and females, who have understood the aims, scope, benefits and risks of the&#xD;
        study as well as study procedures and provide Informed Consent are eligible to participate.&#xD;
        The Study will recruit one hundred and fifty (150) individuals who are known COVID-19&#xD;
        positive (confirmed by RTPCR) and have active infection. The Study will also recruit one&#xD;
        hundred and fifty (150) individuals who are known COVID-19 negative (confirmed by RTPCR&#xD;
        within the last 7 days).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and Females&#xD;
&#xD;
          2. Adults&#xD;
&#xD;
          3. Known COVID-19 positive by RTPCR (with active infection) OR Known COVID-19 negative by&#xD;
             RTPCR (tested within 7 days)&#xD;
&#xD;
          4. Provision of Informed Consent&#xD;
&#xD;
          5. Willing to provide Nasopharyngeal Swab as well as Buccal Cavity Swab&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pediatric patients.&#xD;
&#xD;
          2. Inability to provide Informed Consent.&#xD;
&#xD;
          3. Inability to provide Nasopharyngeal Swab and / or Buccal Cavity Swab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Vivek Manoharan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Test At Home Pte. Ltd., Singapore - India.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Macary, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University, Singapore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saket Jhajharia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Test At Home Pte. Ltd., Singapore - India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Terence Tan, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Test At Home Pte. Ltd., Singapore - India.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vineet Datta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Datar Cancer Genetics Limited, United Kingdom - India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kanupriya Batra, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Test At Home Pte. Ltd., Singapore - India.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vineet Datta, MD</last_name>
    <phone>+919911110457</phone>
    <email>drvineetdatta@datarpgx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dadasaheb Akolkar, PhD</last_name>
    <phone>+917387705888</phone>
    <email>dadasaheb.akolkar@datarpgx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Datar Cancer Genetics</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422010</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Vineet Datta, MD</last_name>
      <phone>+919911110457</phone>
      <email>drvineetdatta@datarpgx.com</email>
    </contact>
    <contact_backup>
      <last_name>Dadasaheb Akolkar, PhD</last_name>
      <phone>+917387705888</phone>
      <email>dadasaheb.akolkar@datarpgx.com</email>
    </contact_backup>
    <investigator>
      <last_name>Vineet Datta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>117597</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Macary, PhD</last_name>
      <email>paul_macary@nuhs.edu.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID19</keyword>
  <keyword>Nasopharyngeal Swab</keyword>
  <keyword>Self Collection</keyword>
  <keyword>Chewable</keyword>
  <keyword>Lollipop</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Individual Participant Data (IPD) may be made available to qualified researchers upon written request with declaration of intent to use and after signing of a Confidentiality Agreement / Non Disclosure Agreement (NDA).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

